BR0010593A - Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv - Google Patents

Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv

Info

Publication number
BR0010593A
BR0010593A BR0010593-7A BR0010593A BR0010593A BR 0010593 A BR0010593 A BR 0010593A BR 0010593 A BR0010593 A BR 0010593A BR 0010593 A BR0010593 A BR 0010593A
Authority
BR
Brazil
Prior art keywords
hiv
ccr5
pegylated
combination therapy
interferon alpha
Prior art date
Application number
BR0010593-7A
Other languages
English (en)
Inventor
Mark A Laughlin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR0010593A publication Critical patent/BR0010593A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "TERAPIA DE COMBINAçãO COM ANTAGONISTA DE CCR5-INTERFERON ALFA PEGUILADO PARA HIV". é divulgado o uso de um interferon-alfa peguilado e de um antagonista de CCR5, também em associação com pelo menos um de ribavirina, IL-2, IL-12, pentafusídeo sozinhos ou em combinação com uma terapia de droga anti-HIV-1, por exemplo, HAART, para a preparação de um medicamento para o tratamento de infecções por HIV-1 assim como de coinfecções por HIV-1 e HCV em pacientes adultos ou pediátricos que nunca receberam tratamento assim como nos que já receberam tratamento.
BR0010593-7A 1999-05-04 2000-05-01 Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv BR0010593A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30489799A 1999-05-04 1999-05-04
PCT/US2000/011634 WO2000066141A2 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Publications (1)

Publication Number Publication Date
BR0010593A true BR0010593A (pt) 2002-02-13

Family

ID=23178462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010593-7A BR0010593A (pt) 1999-05-04 2000-05-01 Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv

Country Status (21)

Country Link
EP (1) EP1175224B1 (pt)
JP (1) JP2002543144A (pt)
CN (1) CN1349408A (pt)
AR (1) AR023824A1 (pt)
AT (1) ATE289516T1 (pt)
AU (1) AU776541B2 (pt)
BR (1) BR0010593A (pt)
CA (1) CA2365900A1 (pt)
DE (1) DE60018273T2 (pt)
ES (1) ES2238277T3 (pt)
HK (1) HK1039278B (pt)
HU (1) HUP0202734A3 (pt)
MX (1) MXPA01011116A (pt)
MY (1) MY127670A (pt)
NO (1) NO328679B1 (pt)
NZ (1) NZ514519A (pt)
PE (1) PE20010283A1 (pt)
PT (1) PT1175224E (pt)
TW (1) TWI289454B (pt)
WO (1) WO2000066141A2 (pt)
ZA (1) ZA200108870B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
TWI344955B (en) 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
JPWO2004092136A1 (ja) * 2003-04-18 2006-07-06 小野薬品工業株式会社 含窒素複素環化合物およびその用途
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
ATE374838T1 (de) 2004-04-29 2007-10-15 Hoffmann La Roche Nukleotidsequenzvariation im gen ns5a als marker
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
BRPI0609251A2 (pt) * 2005-02-23 2010-03-09 Schering Corp derivados de piperidinil piperazina úteis como inibidores de receptores de quimiocinas
JPWO2006129679A1 (ja) 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US8318931B2 (en) 2005-10-28 2012-11-27 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
JP5217438B2 (ja) 2005-11-18 2013-06-19 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US9187451B2 (en) 2011-11-18 2015-11-17 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
CN105899219B (zh) 2014-01-08 2021-08-13 免疫创新治疗有限公司 人类免疫缺陷病毒/获得性免疫缺陷综合症的治疗
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU7473096A (en) * 1995-11-02 1997-05-22 Schering Corporation Continuous low-dose cytokine infusion therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos

Also Published As

Publication number Publication date
HK1039278A1 (en) 2002-04-19
PE20010283A1 (es) 2001-03-16
AU776541B2 (en) 2004-09-16
AU4681500A (en) 2000-11-17
NZ514519A (en) 2003-07-25
HK1039278B (zh) 2005-06-30
ATE289516T1 (de) 2005-03-15
CN1349408A (zh) 2002-05-15
MY127670A (en) 2006-12-29
WO2000066141A3 (en) 2001-02-08
TWI289454B (en) 2007-11-11
HUP0202734A3 (en) 2003-11-28
NO20015367D0 (no) 2001-11-02
ES2238277T3 (es) 2005-09-01
PT1175224E (pt) 2005-07-29
JP2002543144A (ja) 2002-12-17
CA2365900A1 (en) 2000-11-09
NO328679B1 (no) 2010-04-26
HUP0202734A2 (hu) 2002-12-28
MXPA01011116A (es) 2002-06-04
EP1175224B1 (en) 2005-02-23
NO20015367L (no) 2002-01-03
DE60018273D1 (de) 2005-03-31
AR023824A1 (es) 2002-09-04
ZA200108870B (en) 2003-03-26
WO2000066141A2 (en) 2000-11-09
EP1175224A2 (en) 2002-01-30
DE60018273T2 (de) 2005-08-18

Similar Documents

Publication Publication Date Title
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
BR0114636A (pt) Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
BR9910505A (pt) Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
ES2251196T3 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica.
PE119199A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
BR9810745A (pt) Derivados de benzimidazol
BR0108997A (pt) Terapia imune adjuvante para hiv
BR9808303A (pt) O uso de levobupivacaìna na cirurgia facial
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
PT91524A (pt) Processo de preparacao de um medicamento a base de fraccoes e/ou fragmentos de heparina
BR9807473A (pt) Tratamentos de doença relacionados à citocina
BR9915644A (pt) Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus
HK1056838A1 (en) Use of agent for suppressing infection and proliferation of human immunodeficiency syndrome virus.
BR0311696A (pt) Tratamento de hepatite c na população asiática com interferon-beta subcutâneo
WO2000051631A3 (en) Pegylated alpha interferon for hiv therapy
BR9713514A (pt) Novo uso de creatina
BRPI0409711A (pt) tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina
ECSP003462A (es) Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k)
WO2000043014A8 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM ART. 24, ART. 8O COMBINADO COM ART. 11, ART. 10, ART. 25 E ART. 6 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.